Kornimate/medical-research-clean huggingface dataset:
high-intensity interval circuit training in people with parkinson disease

Conditions: Parkinson Disease

Summary: the goal of the study is to compare different types of high intensity circuit exercises over an 8-class training series in people with parkinson disease. the main question it aims to answer is: -does including arm and hand exercises with leg exercises improve reaction time, balance, functional measures, gait speed and quality of life? this group will be compared to a group that only does leg exercises. participants will be asked to participate in 8 high intensity circuit exercise classes.

people with parkinson disease will be recruited from the community and randomized into 2 equal groups: high intensity interval circuit training with lower extremity (le) and lower and upper extremity (leue) training. the study will be composed of a baseline assessment, 8 group class sessions, and a post-intervention assessment. the baseline assessment will include demographics, disease and fall history and outcome measure collection. group class sessions will include concurrent group warmup, followed by an 8-station circuit performed with high intensity intervals, and a cool-down. the circuit will include 4 stations performed by both the le and leue groups and 4 stations specific to each intervention group, including 4 additional le exercise stations for the le group and 4 ue specific stations for the leue group. the stations that differ will not be adjacent to one another nor specifically indicated as different. the stations that differ will mirror similar aspects of function (ie, strength, reaction time, etc.) for the ue and le stations. participants will be told exercise stations may vary within-session and week to week but will not be informed that only one group has ue exercise interventions. after conclusion of the class series, post-intervention balance and stepping outcomes will be reassessed.

Eligibility criteria:
inclusion criteria: * diagnosis of parkinson's disease * hoehn and yahr level of 1 to 3 * ability to walk independently with or without an assistive device * obtain medical clearance to participate in moderate or vigorous exercise. exclusion criteria: * diagnosis of any neurological disease other than pd (including but not limited to stroke, dementia, and multiple sclerosis; mild cognitive impairment is not excluded) * bone instability (non-consolidated fractures, unstable spinal column, severe osteoporosis) * muscle or ligament tears * uncontrolled hypertension * uncontrolled diabetes * severe cardiovascular disease that impairs walking or exercise * a major change in medication during the study training period (pre-test to post-test)

Keywords: exercise
perio treatment & cerebrovascular function

Conditions: Periodontitis

Summary: periodontitis has been linked to increased risk of cerebrovascular disease. impaired brain hemodynamics has been suggested as early markers of cerebral macro and microangiopathy. therefore, the aim of this clinical trial will be to assess the potential effect of periodontal treatment on cerebral hemodynamics in otherwise healthy patients with severe periodontitis over 6 months.


Eligibility criteria:
inclusion criteria: * otherwise healthy subjects with severe periodontitis. exclusion criteria: * \<10 teeth * current smokers * undergo periodontal treatment within the last 6 months. * receive antibiotics or anti-inflammatory drugs within the last 3 months.
assessment of adherence to new oral anticoagulants in atrial fibrillation patients within the outpatient registry

Conditions: Atrial Fibrillation

Summary: a prospective non-interventional single-centre study aimed to evaluate actual adherence of af patients using the validated adherence scale. primary study objective(s) primary study objective the aim of the present study is to assess adherence to therapy and factors associated with adherence in patients with cv disease complicated by non-valvular atrial fibrillation requiring oac treatment within the outpatient registry profile (prospective, observational study). 1. data collection in patients with non-valvular atrial fibrillation requiring oac treatment included in the registry 2. evaluation of actual patient adherence to oacs secondary study objective(s) 1. evaluation of potential patient adherence to oacs 2. determination of the most significant factors associated with adherence to oacs in patients with non-valvular af 3. validation of new original 5-item questionnaire 4. evaluation of doctor's adherence to oac prescription according to guidelines (esc). management of atrial fibrillation,2016)

af patients from ongoing profile registry will be invited to visit the scientific center. 2 visits with a 6-month interval are expected for each patient as part of routine clinical practice and phone contact is scheduled for each patient 1 year from the first visit to the scientific center (follow-up period).

Eligibility criteria:
inclusion criteria: * men and women above 18 years of age who were included in the profile registry by the start of the observational study * presence of written informed consent to participate in the study, fill in the study questionnaires and have personal data analyzed * presence of any form of non-valvular atrial fibrillation with cha2ds2-vasc score of ≥1 or patients with cha2ds2-vasc score = 0, who are already taking oak exclusion criteria: * patients with high bleeding risk, including patients with: * congenital or acquired bleeding disorders * uncontrolled resistant hypertension * exacerbation of gastric and duodenal ulcer * vascular retinopathy * recent history of intracranial or intracerebral hemorrhage * pathology of the brain and spinal cord vessels * recent history of brain, spinal cord or eye surgery * history of bronchiectasis or pulmonary hemorrhage * a cha2ds2-vasc score of 0 (oacs are not indicated) * pregnancy, lactation * planned surgery * known hypersensitivity to ingredients of medications used in the study

Keywords: adherence new oral anticoagulants (noacs) af
a 42-day parallel group safety study of revefenacin and formoterol, administered in sequence and as a combination, in participants with copd

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the primary objective of the study was to characterize the safety and tolerability of once-daily revefenacin inhalation solution when dosed sequentially with twice-daily formoterol inhalation solution (perforomist®) compared to perforomist®, in a population of participants with moderate-to-very severe chronic obstructive pulmonary disease (copd) over 21 days.


Eligibility criteria:
inclusion criteria: * participant is a male or female subject 40 years of age or older. * participant is willing and able to provide signed and dated written informed consent. * participant has a current or past cigarette smoking history (or equivalent for cigar or pipe smoking history) of at least 10 pack-years. * participant must be willing and able to attend study visits according to the visit schedule and adhere to all study assessments/procedures. exclusion criteria: * participant has a concurrent disease or condition that, in the opinion of the investigator, would interfere with study participation or confound the evaluation of safety, tolerability, or pharmacokinetics of the study drug. * participant has a history of reactions or hypersensitivity to inhaled or nebulized anticholinergics, short-acting beta-agonists and long-acting beta-agonists. * participant with clinically significant and uncontrolled hypertension, hypercholesterolemia or type ii diabetes mellitus, as assessed by the investigator. * participant is unwilling or unable to stop the use of prohibited medications during the washout (if required) and treatment period and follow-up period of the study.

Keywords: chronic obstructive pulmonary disease pulmonary function copd performist
synchronise: lvo triage timing and outcome study

Conditions: Stroke, Ischemic

Summary: the objective of this study is to evaluate the impact of viz lvo in hospital systems with non-interventional and interventional (spoke and hub) stroke centers on the timing and outcomes of patients with suspected acute ischemic stroke indicated for mechanical thrombectomy.

this is a multi-center, non-randomized observational study of acute ischemic stroke patients whose cta scans are analyzed by viz lvo to support clinicians in making stroke triage decisions,. the study results will be compared to a cohort from enrolling centers prior to viz lvo implementation that will serve as a historical control. data will be collected retrospectively from the time of presentation through 90 days post discharge. the study will include patients undergoing imaging for a suspected lvo acute ischemic stroke. the post-viz lvo intervention group will consist of patients who either presented to or underwent transfer to an interventional center, from a non-interventional center, following image analysis by viz lvo. data will be collected retrospectively on consecutive patients meeting eligibility criteria from the date of implementation up to 5 years post implementation. the control group will consist of patients who either presented to or underwent transfer to an interventional center, from a non-interventional center, for evaluation prior to the implementation of viz lvo. data will be collected on consecutive patients from one day prior to implementation, back as far as 2 years prior to implementation

Eligibility criteria:
inclusion criteria: * age of 18 years or greater * signs and symptoms consistent with the diagnosis of a large vessel occlusive stroke * pre-treatment national institutes of health stroke scale (nihss) ≥ 6 * aspects score ≥6 * patient must have a suspected lvo in m1. * patient with an intention to treat with mechanical thrombectomy with confirmation of lvo by the ct/cta radiographic report with the reading diagnosis. exclusion criteria: * unable to undergo a brain imaging (i.e. severe contrast medium allergy, claustrophobia)

Keywords: artificial intelligence large vessel occlusion
nature of the link between executive functions and theory of mind in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to explore inhibition and inference abilities in the theory of mind skills in multiple sclerosis patients using the theory of mind task.

multiple sclerosis is an autoimmune inflammatory disease of the central nervous system. it can cause lesions responsible for motor, ocular, sensory and cognitive symptoms. the theory of mind and the primary facial emotions recognition (anger, joy, fear, surprise, sadness, disgust) are two processes of social cognition that play a role in the social interactions and social reasoning. the theory of mind is defined by the ability to understand the other person including thoughts, beliefs and desires that are unique and that may be different from our own. in multiple sclerosis, difficulties in social cognition are associated with cognitive disorders, (even if the link with a deficit in executive functions remains debated). indeed, when attributing a mental state to another person is needed,it is mandatory to put ourselves in the other person's place to adopt another perspective. thus, several executive functions are required: working memory to maintain and manipulate several perspectives, flexibility to switch from one perspective to another one, and finally the inhibition of our own perspective to adopt the other's point of view. the theory of mind's assessment uses nonverbal false belief task which assesses the ability to inhibit its own perspective to infer the mental state of another and the ability to change its perspective to adopt another's. thus, the purpose of this study is to explore inhibition and inference abilities in the theory of mind skills in multiple sclerosis patients using the theory of mind task.

Eligibility criteria:
inclusion criteria: people : * with multiple sclerosis * age ≥ 18 years old * not objecting to the use of their data exclusion criteria: * any associated neurological pathology or severe or chronic somatic disease (cancer) * visual and/or auditory disorders that do not allow for test taking * uncontrolled major psychiatric disorders * recent treatment with corticosteroids (less than 4 weeks before the evaluation) * patients under guardianship, curatorship or safeguard of justice * pregnant women

Keywords: multiple sclerosis theory of mind nonverbal false belief task cognitive functions inhibition and inference abilities
sero-prevalence of coronavirus disease 2019 (covid-19) in healthcare workers

Conditions: COVID; Corona Virus Infection

Summary: the medical and paramedical staff of the front-line services are potentially exposed to sars-cov-2. therefore, despite the application of standard protective measures, it is possible that a certain number of these personnel have already contracted sars-cov-2, including in its asymptomatic form. serological testing in this context would be useful for deploying immune healthcare workers as to limit the risk of viral infection and transmission. therefore, it is of utmost importance to prove that the serological response entails the production of neutralizing antibodies.


Eligibility criteria:
inclusion criteria: * not previously diagnosed with covid-19 except for convalescents * not currently symptomatic with fever or respiratory symptoms (cough, dyspnea) exclusion criteria: * patients with fever or respiratory symptoms (cough, dyspnea) * refusal to give informed consent, or contraindication to venipuncture.
mri - guided adaptive radiotherapy for dysphagia in head and neck cancer

Conditions: HNSCC

Summary: recently developed hybrid machines (mridian®-ce approval since 2016), consisting of a linear accelerator and an integrated low-field mri, could allow better visualization of tumor and organs at risk during patient positioning and daily treatment finally repetitive adaptation of target volumes according to changes in patient weight and tumor anatomy during the radiotherapy course. these procedures would facilitate a high-precision treatment and help reduce dose exposure of critical structures.


Eligibility criteria:
inclusion criteria: 1. age 18-70 years old; 2. i-ivb stage oral cancer, hypopharyngeal cancer, laryngeal cancer, oropharyngeal cancer confirmed by histopathology or cytology (ajcc 8th edition); 3. receiving radical synchronous radiotherapy and chemotherapy; 4. according to the recist version 1.1 evaluation criteria, at least one measurable lesion is present; 5. ecog ps score 0-1; 6. hematology indicators are basically normal: white blood cell count ≥ 4 × 109/l； absolute neutrophil count ≥ 1.5 × 109/l； platelets ≥ 100 × 109/l； hemoglobin ≥ 90g/l; kidney function is basically normal: serum creatinine ≤ 1.5 × uln or creatinine clearance rate (crcl)\>60 ml/min (using cockcroft fault formula): female crcl=(140 age) × body weight (kg) × 0.85 / (72 × scr mg/dl)； male crcl=(140 age) × body weight (kg) × 1.00 / (72 × scr mg/dl) liver function is basically normal: serum total bilirubin ≤ 1.5 × uln； cereal grass transaminase (ast) ≤ 2.5 × uln； glutamate transaminase (alt) ≤ 2.5 × uln； 7. having sufficient cognitive ability to complete the questionnaire survey; 8. able to understand and willing to sign a written informed consent form. exclusion criteria: 1. there is evidence of swallowing dysfunction (unrelated to hnscc); 2. patients who have previously received radiotherapy for the head and neck region; 3. recurrent or metastatic patients; 4. involvement of posterior pharyngeal wall, posterior ring, and posterior pharyngeal lymph nodes; 5. previous tumor resection surgery or major head and neck surgery (excluding biopsy/tonsillectomy); 6. previous tracheotomy; 7. participated in other interventional clinical trials within 30 days prior to screening; 8. individuals with a history of other malignant tumors (excluding cured skin basal cell carcinoma) 9. there are concurrent diseases with poor control (such as heart failure, severe lung disease, severe liver disease, mental illness, etc.); 10. individuals who are allergic to the use of drugs or their components in this protocol; 11. pregnant (confirmed by blood or urine hcg testing) or lactating women, or subjects of childbearing age who are unwilling or unable to take effective contraceptive measures (applicable to both male and female subjects) until at least 6 months after the last trial treatment; 12. researchers believe that it is not suitable to participate in this study; 13. those who are unwilling to participate in this study or unable to sign an informed consent form;
understanding the transition from normal melanocytes to nevus to melanoma

Conditions: Congenital Melanocytic Nevi; Melanoma, Skin; Nevi and Melanomas

Summary: the primary objective of this study is to identify the molecular identity profiles of all cellular states that characterize the progression from benign nevi to malignant melanoma in caya patients with l/gcmn. the secondary objectives are: * to longitudinally characterize the cell-free dna (cfdna) from caya patients. * to improve the early diagnosis and treatments for intermediate conditions such as l/gcmn through evidence-based interpretation of personal risk from endogenous or exogenous sources. * to test pre-clinical strategies to best model and improve patient response.

nevustomel is an international multicentric retrospective cohort study with molecular and experimental design. it will involve the genomic characterization of cell-free dna and affected tissues from patients. methylomics and single-cell multi-omics will be used to identify co-existing molecular (transcriptional and epigenomic) states at single-cell level and will be generated from affected tissues. these results will be exploited using machine learning-assisted integration of multi-modal transcriptomics, epigenomics and spatial information. integrated analyses of single-nucleus rna sequencing from a selection of frozen tissues and spatial transcriptomics on formalin-fixed paraffin-embedded samples will allow the comparison of the findings to ground-state human developmental cell atlas data. distinctions will be validated either with in situ hybridization (such as rna sequencing) or immunostaining on test cohort tissues. these results will be complemented with in vitro functional analyses, high throughput sequencing and bioinformatic analyses.

Eligibility criteria:
inclusion criteria: * congenital nevus with estimated size of 20 cm * be over 18 years of age exclusion criteria: * no available biological material * not having signed the informed consent

Keywords: congenital melanocytic nevi melanoma liquid biopsy cfdna methylomics l/gcmn rnaseq molecular profiles
cigarette smoke and susceptibility to influenza infection

Conditions: Healthy

Summary: this study will be a descriptive comparison of the effects of live attenuated influenza virus (flumist) on nasal inflammation and oxidative stress in healthy young adults who are not exposed to smoke vs smokers. it is hypothesized that passive exposure to second-hand smoke (shs) results in increased susceptibility to the effects of influenza virus in nasal epithelium in humans and that these effects are mediated by shs-induced oxidative stress

epidemiologic evidence supports a significant relationship between passive cigarette smoke exposure and increased risk for viral respiratory illnesses. published and preliminary data suggest that airborne pollutants including tobacco smoke increase susceptibility of respiratory epithelium to infection with influenza a and that this effect is at least partially mediated by oxidative stress. however, no studies have specifically looked at the interaction between smoking and the effects of influenza virus in human volunteers.

Eligibility criteria:
inclusion criteria: * age 18-35 years * healthy nonsmoking who are rarely exposed to shs or smokers exclusion criteria: * pregnancy or nursing; * history of egg allergy; * aspirin therapy; * asthma; * immunodeficiency (hiv or other); * on immunosuppressive drugs including corticosteroids; * history of guillain-barre syndrome; * any chronic medical condition; * febrile and/or respiratory illness within past 3 weeks prior to entry into study; * prospective subjects with high baseline antibody titers against influenza will be excluded because they may be less likely to develop viral replication with laiv.

Keywords: live attenuated influenza virus inflammation flu vaccine flumist smokers
the effects of butyrate enemas on visceral perception

Conditions: Visceral (Hyper)Sensitivity

Summary: during this double blind, placebo controlled, randomised cross over study, healthy volunteers received an enema once daily for one week containing either placebo (saline), 50mm butyrate or 100mm of butyrate. before and directly after each test period a barostat protocol was performed to measure parameters for visceral perception.


Eligibility criteria:
inclusion criteria: * healthy exclusion criteria: * age, under 18 or over 65 * use of pre- or probiotics during study and 3 months previous to study * previous bowel complaints * gastrointestinal disease or abdominal surgery

Keywords: butyrate, visceral perception, compliance
ffa hypertension and inflammation in lean and obese subjects

Conditions: Diabetes; Hypertension; Obesity

Summary: although a large number of obese patients develop high blood pressure, the cause is unknown. the purpose of this study is to look at the effect of high fatty acids (a type of fat) in the development of high blood pressure in obese people.

recent studies indicate that increased levels of a circulating fat (free fatty acids or ffas) increases blood pressure, impairs endothelial (vascular) function, and increases inflammatory markers in subjects with and without diabetes. the effects of ffa on blood pressure and vasculature have not been fully investigated. a group of 12 obese nondiabetic, normotensive subjects will be admitted to the grady clinical research center (gcrc) on separate 4 occasions. research subjects will receive, in random order, a 8-hour intravenous (iv) infusion of intralipid 20% at 40 ml/h (a fat solution), 8-hour iv infusion of normal saline at 40 ml/h, 8-hour iv infusion of dextrose (sugar) 10% at 40 ml/h, and a 8-hour intravenous (iv) infusion combination of intralipid 20% and dextrose 10% at 40ml/h.

Eligibility criteria:
inclusion criteria: * males or females * obese subjects (body mass index (bmi) ≥ 30 kg/m\^2) * 18 and 65 years * blood pressure reading \< 140/80 mm hg and no prior history of hypertension exclusion criteria: * history of diabetes mellitus * history of hypertension * fasting triglyceride levels \> 250 mg/dl * liver disease (alt 2.5x \> upper limit of normal) * serum creatinine ≥1.5 mg/dl * smokers, drug or alcohol abuse * mental condition rendering the subject unable to understand the scope and possible consequences of the study * female subjects who are pregnant or breast feeding